We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+39.96%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$3.39B
AUM Growth
+$491M
Cap. Flow
-$128M
Cap. Flow %
-3.78%
Top 10 Hldgs %
67.91%
Holding
89
New
9
Increased
10
Reduced
15
Closed
13

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$99.2M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$75.1M
3
GOSS icon
Gossamer Bio
GOSS
+$51.6M
4
KYMR icon
Kymera Therapeutics
KYMR
+$21M
5
CNTA
Centessa Pharmaceuticals
CNTA
+$13.5M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$118M
2
RVMD icon
Revolution Medicines
RVMD
+$54.4M
3
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$53.7M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$43.5M
5
ARGX icon
argenx
ARGX
+$39.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.27%
2 Financials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FLAC
51
DELISTED
Frazier Lifesciences Acquisition Corporation Class A Ordinary Shares
FLAC
$4.86M 0.14%
487,615
-100,000
-17% -$993K
ALGS icon
52
Aligos Therapeutics
ALGS
$26.3M
$4.34M 0.13%
157,934
– –
SURF
53
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$4.08M 0.12%
3,924,713
-728,287
-16% -$1.16M
OBIO icon
54
Orchestra BioMed
OBIO
$231M
$3.96M 0.12%
400,000
– –
PRAX icon
55
Praxis Precision Medicines
PRAX
$8.25B
$3.4M 0.1%
99,755
+85,748
+612% +$4.27M
MGNX icon
56
MacroGenics
MGNX
$245M
$3.22M 0.1%
+930,955
New +$3.56M
ASND icon
57
Ascendis Pharma A/S
ASND
$16.7B
$2.81M 0.08%
+27,208
New +$2.58M
NUVB.WS
58
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$2.16M 0.06%
963,333
– –
KNTE
59
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.09M 0.06%
175,000
– –
EUCR
60
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$2M 0.06%
200,000
– –
BLSA
61
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$2M 0.06%
200,000
– –
FVAM
62
DELISTED
5:01 Acquisition Corp
FVAM
$2M 0.06%
200,000
– –
TPST icon
63
Tempest Therapeutics
TPST
$13.9M
$1.79M 0.05%
79,328
– –
ARYD
64
DELISTED
ARYA Sciences Acquisition Corp IV Class A Odinary Shares
ARYD
$1.49M 0.04%
150,000
– –
KRON
65
DELISTED
Kronos Bio
KRON
$1.09M 0.03%
326,780
– –
DSGN icon
66
CALL
Design Therapeutics
DSGN
$741M
$1.06M 0.03%
+63,400
New +$1.26M
TMPM
67
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$1M 0.03%
100,000
– –
RETA
68
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$967K 0.03%
38,467
-1,937,144
-98% -$53.7M
NUVL
69
DELISTED
Nuvalent
NUVL
$796K 0.02%
+40,970
New +$686K
ITOS
70
DELISTED
iTeos Therapeutics
ITOS
$771K 0.02%
40,480
-239,519
-86% -$5.52M
CMAXW
71
DELISTED
CareMax, Inc. Warrant
CMAXW
$709K 0.02%
100,000
– –
EUCRW
72
DELISTED
Eucrates Biomedical Acquisition Corp. Warrant
EUCRW
$668K 0.02%
66,666
– –
FLACW
73
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
$665K 0.02%
66,665
– –
OMEG
74
DELISTED
Omega Alpha SPAC Class A Ordinary Shares
OMEG
$497K 0.01%
50,000
– –
TMPMW
75
DELISTED
Turmeric Acquisition Corp. Warrant
TMPMW
$333K 0.01%
33,333
– –
1 2
3
4

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q3 2022 Portfolio in Review

As of Q3 2022, EcoR1 Capital held 89 positions worth $3.39B, up 17% from $2.9B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital withdrew a net $128M in Q3 2022, closing 13 positions and reducing 15 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $43.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

Against the trend, EcoR1 Capital opened a new position in SpringWorks Therapeutics worth $98.7M.

  • EcoR1 Capital's largest Q3 2022 buy was SpringWorks Therapeutics: 3,460,208 shares worth $98.7M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q3 2022, an estimated $13.5M increase.
  • EcoR1 Capital's biggest Q3 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $118M.
  • EcoR1 Capital fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2022, selling an estimated $43.5M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $3.39B portfolio in Q3 2022.
  • EcoR1 Capital opened 9 new positions and closed 13 in Q3 2022.
  • EcoR1 Capital's portfolio value rose 17% quarter-over-quarter to $3.39B.

Based on EcoR1 Capital's 13F filing for Q3 2022, filed 14 Nov 2022.